Measured Wealth Private Client Group LLC Sells 515 Shares of Eli Lilly and Company (NYSE:LLY)

Measured Wealth Private Client Group LLC lessened its position in shares of Eli Lilly and Company (NYSE:LLY) by 34.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 997 shares of the company’s stock after selling 515 shares during the period. Measured Wealth Private Client Group LLC’s holdings in Eli Lilly and Company were worth $776,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Alps Advisors Inc. raised its holdings in shares of Eli Lilly and Company by 86.8% in the 3rd quarter. Alps Advisors Inc. now owns 33,288 shares of the company’s stock valued at $17,880,000 after acquiring an additional 15,471 shares in the last quarter. Elevatus Welath Management purchased a new position in Eli Lilly and Company in the 3rd quarter worth approximately $371,000. EHP Funds Inc. bought a new position in shares of Eli Lilly and Company in the 3rd quarter worth $269,000. Legacy Advisors LLC raised its position in shares of Eli Lilly and Company by 14.7% during the 3rd quarter. Legacy Advisors LLC now owns 2,045 shares of the company’s stock valued at $1,098,000 after buying an additional 262 shares in the last quarter. Finally, Lakeshore Financial Planning Inc. purchased a new position in Eli Lilly and Company in the third quarter worth $263,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms have weighed in on LLY. Truist Financial restated a “buy” rating and set a $1,000.00 price target (up previously from $892.00) on shares of Eli Lilly and Company in a research report on Tuesday, June 25th. JPMorgan Chase & Co. upped their target price on Eli Lilly and Company from $850.00 to $900.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 1st. Bank of America restated a “buy” rating and issued a $1,000.00 price objective on shares of Eli Lilly and Company in a report on Monday, June 24th. Jefferies Financial Group increased their target price on shares of Eli Lilly and Company from $994.00 to $1,015.00 and gave the company a “buy” rating in a report on Monday, June 24th. Finally, TheStreet raised shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. Three research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $812.72.

Eli Lilly and Company Trading Down 0.8 %

Shares of NYSE:LLY traded down $7.66 on Tuesday, hitting $906.71. The company had a trading volume of 4,526,567 shares, compared to its average volume of 2,947,025. Eli Lilly and Company has a 1 year low of $434.34 and a 1 year high of $916.83. The company has a quick ratio of 1.03, a current ratio of 1.35 and a debt-to-equity ratio of 1.90. The firm’s 50-day simple moving average is $818.06 and its two-hundred day simple moving average is $743.26. The firm has a market capitalization of $861.75 billion, a price-to-earnings ratio of 133.54, a P/E/G ratio of 1.97 and a beta of 0.41.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Monday, May 6th. The company reported $2.58 earnings per share for the quarter, beating the consensus estimate of $2.53 by $0.05. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The business had revenue of $8.77 billion for the quarter, compared to analysts’ expectations of $8.94 billion. During the same period in the previous year, the firm posted $1.62 EPS. The business’s revenue was up 26.0% on a year-over-year basis. Equities analysts anticipate that Eli Lilly and Company will post 13.76 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Thursday, August 15th will be given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 0.57%. The ex-dividend date of this dividend is Thursday, August 15th. Eli Lilly and Company’s dividend payout ratio is currently 76.58%.

Insider Transactions at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 58,749 shares of the business’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $915.26, for a total transaction of $53,770,609.74. Following the sale, the insider now owns 97,308,620 shares of the company’s stock, valued at $89,062,687,541.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 58,749 shares of Eli Lilly and Company stock in a transaction on Monday, July 1st. The stock was sold at an average price of $915.26, for a total transaction of $53,770,609.74. Following the completion of the transaction, the insider now owns 97,308,620 shares in the company, valued at $89,062,687,541.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Johna Norton sold 7,056 shares of the stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $819.38, for a total value of $5,781,545.28. Following the completion of the sale, the executive vice president now directly owns 25,428 shares in the company, valued at $20,835,194.64. The disclosure for this sale can be found here. Insiders have sold 849,894 shares of company stock valued at $727,475,118 in the last three months. 0.13% of the stock is currently owned by company insiders.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.